Before you scale to the U.S., know where your IP value lives.
When an Israeli startup expands to the U.S., a common setup is a U.S. parent company, Israeli R&D arm, and fast-growing U.S. sales. At first it looks ideal. But the decisive factor is often overlooked: who legally owns the IP?
What CFOs should double-check before expansion.
In today’s tax environment, owning IP in Israel versus the U.S. can create very different implications. The right answer depends on business substance, transfer pricing, investor expectations, and the company’s long-term exit strategy.
Legal IP Ownership
Confirm which entity owns the technology, patents, source code, trademarks, and future development rights.
Transfer Pricing
Ensure intercompany charges reflect real functions, risks, assets, and arm’s-length economics.
Profit Allocation
Model how profits should be split between U.S. commercial activity and Israeli development activity.
M&A Readiness
Prepare documentation buyers and investors expect to see during tax, legal, and financial diligence.
The Disconnect We Keep Seeing
On paper many firms say “IP is in Israel” – but in practice the U.S. unit books nearly all revenue and margins. The Israeli subsidiary often operates merely as a cost center. Tax authorities expect the profits to follow the IP owner. In other words, if Israel truly owns the IP, Israel should report most of the related income. When U.S. sales and profits sit in America instead, that mismatch guarantees scrutiny.
In our experience, U.S. and Israeli auditors will question any structure where the Israeli side does R&D but earns little, while the U.S. side reaps the profits. Reality vs. paperwork: On paper the IP may sit in Israel, but in reality U.S. books show the gains. Revenue and COGS are booked by the U.S. entity, while Israel just incurs development expenses. This economic pattern conflicts with arm’s‑length principles.
- Tax baseline: Both U.S. and Israeli tax rules dictate that the country of IP ownership should see the returns. If that isn’t happening, authorities can reallocate profit. For example, Israel’s tax authority has long questioned whether local R&D deserves a mere markup or a share of profits – effectively treating Israel as an IP owner unless properly documented.
Without clear transfer pricing and documentation, this disconnect creates real risk. Mismatches between where IP “sits” and where profit arises invite audits, tax adjustments, and even double taxation of the same income.
Transfer Pricing Gets Real – Fast
In a U.S. – Israel structure, you can’t defer transfer pricing compliance. If Israel is the legal IP owner, the companies must agree up front on how value moves between them. Key questions include:
- Royalty payments: Does the U.S. unit pay Israel a royalty for IP use? (Any royalty from the U.S. parent to an Israeli owner is subject to U.S. withholding tax, typically capped at 10–15% under the U.S.–Israel tax treaty.)
- Cost-sharing or profit split: Do the U.S. and Israeli entities share R&D costs and future profits according to a formula?
- Functions and responsibilities: Who handles what? The Israeli side may focus on development, the U.S. side on marketing and sales. But these roles must be clearly codified.
If no formal model exists, both the IRS and Israel Tax Authority will challenge the arrangement. They will expect an arm’s-length transfer pricing study and intercompany contracts. For example, Israel now requires an annual tax form that includes the intercompany R&D services agreement and a full transfer pricing analysis. (And under new rules, an Israeli R&D subsidiary must meet strict conditions – foreign parent control, proper R&D contracts, cost-plus margin, etc. – to rely on a simple cost-plus method.) Absent these, any transfer pricing claims may be overturned. The result can be painful: each country can assert additional tax on the same profits, effectively taxing income twice.
| Area | Key Question | Why It Matters | Action |
|---|---|---|---|
| Royalty Payments | Does the U.S. entity pay for IP use? | May trigger withholding tax and affects profit allocation | Define royalty structure and document it |
| Cost Sharing | Are costs and profits shared? | Impacts how value is split between entities | Set clear allocation model |
| Functions | Who does development, sales, decisions? | Authorities look at real activity, not just structure | Document roles clearly |
| Compliance | Is there a transfer pricing study? | Required by IRS and Israel Tax Authority | Prepare documentation annually |
The Part That Catches Founders Off Guard
Even when transfer pricing is set up “correctly,” there is another big surprise: the U.S. can tax foreign profits even if no cash is repatriated. Under the TCJA, U.S. shareholders of a controlled foreign corporation (CFC) must include certain types of foreign income in their U.S. taxable income each year (the GILTI rules). In practice, this means a U.S. parent can owe U.S. tax on its Israeli subsidiary’s earnings without any dividends. If the Israeli subsidiary’s effective tax rate is below the U.S. minimum, the U.S. looks at that excess as implicitly repatriated. This catches many founders off guard once they hit profitability.
Israel Adds Another Layer
Keeping IP in Israel can be appealing (see below), but it brings its own complexities:
- Withholding on royalties: If the Israeli entity licenses IP to the U.S., any royalties flow back to Israel are subject to U.S. withholding tax (10–15% under the treaty). Conversely, if the U.S. parent owns IP and licenses to Israel, Israel would withhold on payments to the U.S. as well (subject to treaty limits). These withholding rates can bite cash flow and must be factored into intercompany pricing.
- Tighter transfer pricing scrutiny: Israeli tax law (Section 85A) requires strict arm’s-length pricing. Any royalties or licenses between the U.S. and Israeli entities will be closely scrutinized. The Israeli Tax Authority now demands intercompany agreements, transfer pricing studies, and cost-plus markups for R&D services. Failure to document the pricing can lead to adjustments.
- IIA funding and IP rules: If the Israeli R&D has received grants from the Israel Innovation Authority (IIA), special rules apply. IP developed with IIA support cannot be transferred outside Israel without approval. If approval is granted, the company must pay a transfer fee (which may be based on grant repayment or future royalties). Importantly, any M&A involving IIA-funded IP triggers IIA oversight: a foreign buyer must secure IIA consent and often pay accelerated royalties or repay grants. These requirements alone can slow deals or push buyers to ask for restructuring.
Exit Is Where This Becomes Very Real
All these issues crystallize at exit. When a startup is acquired, the location of the IP suddenly drives major decisions:
- Restructuring pressure: Buyers want “clean” cap tables and clear IP ownership. If the IP is in Israel, acquirers often push to move it into the U.S. entity (to avoid foreign withholding and IIA constraints). But as noted, transferring IP out of Israel usually requires IIA approval and hefty payments.
- Deal delays: Navigating IIA approvals or transferring IP can slow down or even derail negotiations. Due diligence will expose any transfer obligations. In practice, we see every cross-border exit get dug into for IP compliance.
- Increased tax exposure: On an exit, tax authorities will look for any misalignments. For example, Israel might impose an “exit tax” if it determines that economic rights to the IP were effectively transferred abroad (even if legally the IP was still in Israel).
Two Ways to Structure It
Startups typically end up with one of two approaches:
- U.S. owns the IP: In this model, the U.S. parent holds patents/trademarks. The Israeli arm operates purely as an R&D center (and all R&D costs flow through it). The U.S. company then licenses or acquires any developments from Israel under a cost-sharing or services agreement. Pros: Conceptually simpler transfer pricing (fewer foreign IP payments), easier for U.S. M&A buyers, and U.S. can claim R&D tax credits locally (though note U.S. R&D expenses must be amortized under Sec. 174). Cons: R&D costs (Israeli labor) do not generate U.S. tax deductions immediately (because of the amortization rule), and the group loses the low Israeli tax rate on IP income. Also, U.S. shareholders face Subpart F/GILTI on the Israeli subsidiary’s income .
- Israel owns the IP: Here the Israeli company holds the IP and licenses it to the U.S. entity. Pros: Israel’s encouragement regime offers very low tax on qualifying IP income (often 12%, or 6% for certain preferred tech companies). Israeli payroll costs may also benefit from local R&D incentives. Cons: The structure is more complex. It demands formal arm’s-length agreements, recurring royalty or cost-sharing payments, and compliance with IIA rules if funding was involved. Withholding taxes apply on cross-border royalties, and transfer pricing documentation must be bulletproof.
Where Companies Get Into Trouble
In practice, certain pitfalls recur across startups:
- No transfer pricing policy: Many founders postpone the decision or operate informally. Without intercompany agreements or transfer pricing studies, you’re on shaky ground. Tax authorities will take a dim view of deals “as if at arm’s length.” In Israel, failing to attach an R&D services agreement and transfer pricing study to the annual return is a red flag.
- Profits in the wrong place: Letting the U.S. pocket all the profit (or vice versa) without justification often backfires. If revenues climb but Israel’s taxable income stays artificially low, audits will happen.
- Missing intercompany agreements: Simple things like a royalty or cost-sharing contract are essential. Startups that skip these early find themselves scrambling to draft them later – often under pressure.
- Surprises on scaling or exit: Founders report that a structure that “worked for a while” suddenly causes a headache at Series C, or when investors enter, or at acquisition. A late-stage audit or M&A due diligence can reveal transfer pricing gaps, unclaimed tax obligations, or IIA liabilities that cost the company time and money.
Final Thought
IP location isn’t just an accounting checkbox – it’s a strategic decision with real financial consequences. Getting your corporate structure, IP ownership, and financial model aligned from the start can save millions in tax and eliminate headaches later. Founders should work with tax and legal counsel early to set up intercompany agreements, choose the right jurisdiction for IP, and stay compliant with both U.S. and Israeli rules. That way, as your startup grows or heads to exit, you’ll keep all options open instead of scrambling to fix last-minute surprises.